Shares of Resverlogix Corp. (TSE:RVX – Get Free Report) reached a new 52-week low on Tuesday. The stock traded as low as C$0.07 and last traded at C$0.07, with a volume of 2,850 shares. The stock had previously closed at C$0.07.
Resverlogix Stock Performance
The firm has a fifty day moving average of C$0.09 and a two-hundred day moving average of C$0.10. The company has a market cap of C$25.82 million, a PE ratio of -1.88 and a beta of -0.11. The company has a current ratio of 0.04, a quick ratio of 0.04 and a debt-to-equity ratio of -82.47.
About Resverlogix
Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients’ lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state.
See Also
- Five stocks we like better than Resverlogix
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
